Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy+ G-CSF in patients with chronic myelogenous leukemia in first chronic phase

Leukemia and Lymphoma

Volumn 47, Issue 9, 2006, Pages 1768-1773

  Olsson Strömberg, Ulla ^a   Höglund, Martin ^a   Björkholm, Magnus ^c   Braide, Inger ^d   Carlson, Karin ^f   Gahrton, Gösta ^c   Grimfors, Gunnar ^c   Hast, Robert ^c   Lerner, Rickard ^c   Linder, Olle ^b   Ljungman, Per ^c   Löfvenberg, Eva ^c   Malm, Claes ^f   Nilsson, Per Gunnar ^g   Paul, Christer ^c   Rödjer, Stig ^d   Stenke, Leif ^c   Tidefeldt, Ulf ^b   Turesson, Ingemar ^g   Uden, Ann Marie ^c   Wahlin, Anders ^e   Vilen, Lars ^d   Winqvist, Ingemar ^g   Zettervall, Olle ^g   Öberg, Gunnar ^a   Simonsson, Bengt ^a   more..

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Autologous transplantation; CML; G CSF; Stem cell mobilization

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; IMATINIB; INTERFERON; MITOXANTRONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER SURVIVAL; CD34 SELECTION; CHROMOSOME ANALYSIS; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; COLONY FORMING UNIT GM; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; LEUKAPHERESIS; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; OVERALL SURVIVAL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; SURVIVAL TIME; THROMBOCYTE COUNT; TREATMENT DURATION; WHOLE BODY RADIATION;

EID: 33750479897     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600611117     Document Type: Article

References (39)

1. Gale, R and Hehlmann, R and Zhang, M and Hasford, J and Goldman, J and Heimpel, H and (1998) Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukaemia The German CML Study Group Blood, 91(5), pp. 1810-1819.
2. McGlave, P and De Fabritiis, P and Deisseroth, A and Goldman, J and Barnett, M and Reiffers, J and (1994) Autologous transplants for chronic myelogenous leukaemia: Results from eight transplant groups Lancet, 343, pp. 1486-1488.
3. van Rhee, F and Szydlo, R and Hermans, J and Devergie, A and Frassoni, F and Arcese, W and (1997) Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: A report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant, 20(7), pp. 553-560.
4. Goldman, J. (1997) Optimizing treatment for chronic myeloid leukemia N Eng J Med, 337, pp. 270-271.
5. Long-term follow-up of the Italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. (1998) The Italian Cooperative Study Group on Chronic Myeloid Leukemia Blood, 92(5), pp. 1541-1548.
6. Allan, N and Richards, S and Shepherd, P. (1995) UK Medical Research Council randomised, multicentre trial of interferon-α for chronic myeloid leukaemia: Improved survival irrespective of cytogenetic response Lancet, 345, pp. 1392-1397.
7. Hehlmann, R and Berger, U and Pfirrmann, M and Hochhaus, A and Metzgeroth, G and Maywald, O and (2003) Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): Prolongation of survival by the combination of interferon alpha and hydroxyurea Leukemia, 17(8), pp. 1529-1537.
8. Talpaz, M and Silver, R and Druker, B and Goldman, J and Gambacorti-Passerini, C and Guilhot, F and (2002) Imatinib induces durable hematologic and cytogenetic responses in patients with accelererated phase chronic myeloid leukemia: Results of a phase 2 study Blood, 99, pp. 1928-1937.
9. O'Brien, S and Guilhot, F and Larson, R and Gathmann, I and Baccarani, M and Cervantes, F and (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia New Eng J Med, 348, pp. 994-1004.
10. To, L and Haylock, D and Dowse, T and Simmons, P and Trimboli, S and Ashman, L and (1994) Comparative study of the phenotype and proliferative capacity of peripheral CD 34+ cells mobilized by four different protocols and those of steady - state PB and bone marrow CD 34+ cells Blood, 84(2930).
11. Dewald, G and Wyatt, W and Juneau, A and Carlson, R and Zinsmeister, A and Jalal, S and (1998) Highly sensitive fluorescence in situ hybridization method to detect double BCR/ABL fusion and monitor response to therapy in chronic myeloid leukemia Blood, 91, pp. 3357-3365.
12. Barbany, G and Hagberg, A and Olsson-Stromberg, U and Simonsson, B and Syvanen, A and Landegren, U. (2000) Minifold-assisted reverse transcription-PCR with real time detection for measurement of the BCR-ABL fusion transcript in chronic myeloid leukemia patients Clin Chem, 46, pp. 913-920.
13. Kaplan, E and Meier, P. (1958) Non parametric estimation from incomplete observations J Am Stat Assoc, 53, pp. 457-481.
14. Deisseroth, A and Zu, Z and Claxton, D and Hanania, E and Fu, S and Ellerson, D and (1994) Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukaemia contribute to relapse after autologous bone marrow in CML Blood, 83, pp. 3068-3076.
15. Verfaillie, C and Bhatia, R and Miller, W and Mortari, F and Roy, V and Burger, S and (1996) BCR/ABL-negative primitive progenitors suitable for transplantation can be selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients Blood, 87(11), pp. 4770-4779.
16. Petzer, A and Eaves, C and Lansdorp, P and Ponchio, L and Barnett, M and Eaves, A. (1996) Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia Blood, 88, pp. 2162-2171.
17. Carlo-Stella, C and Regazzi, E and Sammarelli, G and Colla, S and Garau, D and Gazit, A and (1999) Effects of the tyrosine kinase inhibitor AG957 and an Anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells Blood, 93(11), pp. 3973-3982.
18. De Fabritiis, P and Petti, M and Montefusco, E and De Propris, M and Sala, R and Bellucci, R and (1998) BCR-ABL antisense. Oligodoxynucleotide in vitro purging and autologous bone marrow transplantation for patients with chronic myelogenous leukemia in advanced phase Blood, 91, pp. 3156-3162.
19. Heinzinger, M and Waller, C and Rosenstiel, A and Scheid, S and Burger, K and Lange, W. (1998) Quality of IL-3 and G-CSF mobilised peripheral blood stem cells in patients with early chronic phase CML Leukemia, 12, pp. 333-339.
20. Becker, M and Fabrega, S and Belloc, F and Rice, A and Barbu, V and Reiffers, J. (1993) Interferon gamma is effective for BM purging in a patient with CML Bone Marrow Transplant, 12, pp. 155-158.
21. Gewirtz, A. (1994) Treatment of CML with c-myc antisense oligodeoxynucleotides Bone Marrow Transplant, 14(Suppl 3), pp. S57-S61.
22. Luna-Bautista, F and Sanchez-Valle, E and Ayala-Sanchez, M and Morales-Polanco, M and Meillon-Garcia, L and Benitez-Bribiesca, L and (2003) Kinetics of hematopoiesis in bone marrow cultures from patients with chronic myeloid leukemia: Effect of recombinant cytokines in dexter-type long-term cultures Hematology, 8(3), pp. 155-163.
23. Kiehntopf, M and Esquivel, E and Brach, M and Herrmann, F. (1995) Clinical applications of ribozymes Lancet, 345, pp. 1027.
24. Pachuk, C and Yoon, K and Moelling, K and Coney, L. (1994) Selective cleavage of bcr-abl chimeric RNAs by a ribozyme targeted to non-contiguous sequences Nucleic Acids Res, 22, pp. 301.
25. Carella, A and Podesta, M and Frassoni, F and Raffo, M and Pollicardo, N and Pungolino, E and (1993) Collection of "normal" blood repopulating cells during early hematopoetic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia Bone Marrow Transplant, 12, pp. 267-271.
26. Carella, A and Lerma, E and Corsetti, M and Dejana, A and Basta, P and Vassallo, F and (1999) Autografting with philadelphia chromosome-negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia Blood, 93(5), pp. 1534-1539.
27. Fischer, T and Neubauer, A and Mohm, J and Huhn, D and Busemann, C and Link, H and (1998) Chemotherapy - induced mobilisation of karyotypically normal PBSC for autografing in CML Bone Marrow Transplant, 21, pp. 1029-1036.
28. Talpaz, M and Kantarjian, H and Liang, J and Calvert, L and Hamer, J and Tibbits, P and (1995) Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autologous cells Blood, 85, pp. 3257-3263.
29. Simonsson, B and Oberg, G and Bjoreman, M and Bjorkholm, M and Carneskog, J and Gahrton, G and (1996) Danish-Swedish CML Intensive treatment in order to minimize the Ph-positive clone in CML Bone Marrow Transplant, 17((Suppl 3)), pp. S63-S64.
30. Frassoni, F and Podesta, M and Piaggio, G and Rosti, V and Pitto, A and Benvenuto, F and (1999) Normal primitive haemopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukaemia but rapidly decline with time Br J Haematol, 104(3), pp. 538-545.
31. Chalmers, E and Franklin, I and Kelsey, S and Newland, A and Clark, R and Sproul, A and (1997) Treatment of chronic myeloid leukaemia in first chronic phase with idarubicin and cytarabine: Mobilisarion of Philadelphia -negative peripheral blood stem cells Br J Haematol, 96, pp. 627-634.
32. Carella, A and Frassoni, F. (1996) ICE, mini ICE or high-dose hydroxyurea to mobilise Philadelphia negative PBPC in chronic myelogenous leukaemia Br J Haematol, 95, pp. 213-215.
33. Pratt, G and Johnson, R and Rawstron, A and Barnard, D and Morgan, G and Smith, G. (1998) Autologous stem cell transplantation in chronic myeloid leukaemia using Philadelphia chromosome negative blood progenitors mobilised with hydroxyurea and G-CSF Bone Marrow Transplant, 21, pp. 455-460.
34. Carella, A and Beltrami, G and Corsetti, M. (2003) Autografting in chronic myeloid leukemia Semin Hematol, 40(1), pp. 72-78.
35. Khouri, I and Kantarjian, H and Talpaz, M and Giralt, S and Rios, M and Hester, J and (1996) Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukemia: MD Anderson experience Bone Marrow Transplant, 17, pp. 775-779.
36. Mehta, J and Mijovic, A and Powles, R and Pagliuca, A and Singhal, S and Czepulkowski, B and (1996) Myelosuppressive chemotherapy to mobilize normal stem cells in chronic myeloid leukemia Bone Marrow Transplant, 17, pp. 25-29.
37. Simonsson, B and Oberg, G and Bjoreman, M and Bjorkholm, M and Carneskog, J and Karlsson, K and (2005) Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: Long-term follow-up Acta Haematol, 113(3), pp. 155-162.
38. Bhatia, R and Verfaille, C and Miller, J and McGlave, P. (1997) Autologous transplantation therapy for chronic myelogenous leukemia Blood, 89, pp. 2623-2634.
39. Hui, C and Goh, K and White, D and Branford, S and Grigg, A and Seymour, J and (2003) Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR Leukemia, 17(5), pp. 821-828.